Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel medical applications of notoginsenoside R2

A kind of Panax notoginseng saponins, use technology, applied in the field of medicine and pharmacy

Inactive Publication Date: 2020-11-24
INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese invention patent application "A use of notoginseng saponin Ft1" (publication number CN108014118 A, publication date May 11, 2018) discloses that notoginseng saponin Ft1 (structural formula shown in formula III below) has a TGR5 agonistic effect and can improve small Lipid metabolism, glucose metabolism and insulin sensitivity in mice; but other nine saponins including notoginseng saponin R2 have no TGR5 agonistic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel medical applications of notoginsenoside R2
  • Novel medical applications of notoginsenoside R2
  • Novel medical applications of notoginsenoside R2

Examples

Experimental program
Comparison scheme
Effect test

experiment example

[0055] 1. Materials and Experimental Methods

[0056] 20(S)-Notoginsenoside R2 was purchased from Shanghai Ronghe Pharmaceutical Technology Co., Ltd., with a purity of ≥98%.

[0057] 3T3-L1 cells were donated by Professor Guo Peng, Institute of Medicinal Plants, Chinese Academy of Medical Sciences; DMEM (Dulbecco's Modified Eagle Medium) was purchased from Corning Company of the United States; fetal bovine serum was purchased from Gibco Company of the United States; 3-isobutyl-1-formazol Basexanthine (IBMX), insulin (INS) and dexamethasone (DEXA) were purchased from Sigma Company; trypsin solution was purchased from BBI Life Science Company; penicillin-streptomycin solution was purchased from Beijing Soleibao Technology Co., Ltd.; PCR primers were synthesized by Shanghai Sangon Bioengineering Technology Service Co., Ltd.; fluorescence quantitative PCR related reagents were purchased from Takara Company; TG detection kit was purchased from Beijing Zhongsheng Beikong Biotechnolo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel medical applications of notoginsenoside R2. The novel medical application comprises the application to preparation of drugs for preventing and treating obesity and type 2diabetes in mammals, the application to preparation of drugs for promoting browning of white adipocytes in mammals and the application to preparation of drugs for promoting generation of mitochondriain mammals. A new treatment method is provided for diseases related abnormal lipid metabolism such as obesity and type 2 diabetes.

Description

technical field [0001] The invention belongs to the field of medicine and pharmacy, and specifically relates to a new medical application of notoginseng saponin R2 (NGR2). Background technique [0002] Panax notoginseng is the dry root and rhizome of Panax notoginseng (Burk.) F.H.Chen, a plant of the genus Panax notoginseng (Burk.) F.H.Chen in the Araliaceae family. It is mostly used for the treatment of bruises and the like. The total saponins of Panax notoginseng are the main active parts of Panax notoginseng. So far, ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, Rg2, Rh1, Panax notoginsenosides R1, R2, R3, R4, R6, etc. have been isolated for 20 years. A variety of saponins; among them, ginsenosides Rb1, Rg1 and notoginsenoside R1 have the highest content. [0003] Notoginseng saponin R2 has two stereoisomers, 20(S) and 20(R), and the specific structures are shown in the following formulas I and II. [0004] [0005] It has been reported that notoginseng saponin R2 has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P3/10A61P3/06A61P3/04
CPCA61K31/704A61P3/04A61P3/06A61P3/10
Inventor 金文熊燕匡世焕孙晓波孙桂波张彬
Owner INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com